Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02761369
Other study ID # SOR-0324-15-CTIL
Secondary ID
Status Recruiting
Phase N/A
First received April 20, 2016
Last updated January 2, 2018
Start date June 18, 2017
Est. completion date June 2018

Study information

Verified date June 2017
Source Soroka University Medical Center
Contact Roni Aviram-Friedman, PhD
Phone 19292245107
Email aviramro@bgu.post.ac.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The neurobiological underpinnings of obesity point to brain asymmetry in cortical and deeper brain regions. Furthermore, chemical, structural and functional imbalance in cortical and sub-cortical brain regions alters reward processing, attentional control and self-regulation in food-addicted obese individuals. In this study the investigators use TMS with a special multichannel H-coil developed by their lab to safely stimulate cortical and deeper brain regions in obese humans. The investigators aim to produce interhemispheric neuroplasticity (INP) using a paired associative stimulation (PAS) protocol over the DLPFC, to restore neurobiological functioning, alleviate food addiction symptoms, and promote weight loss.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 2018
Est. primary completion date June 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years to 70 Years
Eligibility Inclusion Criteria:

- 30 = BMI = 40.

- Having had at least one prior conventional weight loss attempt, but no current weight loss attempts or over the last 3 months.

- Having satisfied a safety screening questionnaire for TMS (Keel, 2001)

- Omnivorous

- Have not had experience with TMS of any kind

Exclusion Criteria:

- The participant experiences tremor in any limb.

- The participant experiences seizures.

- The participant has a history of epilepsy or seizure (EXCEPT those therapeutically induced by ECT), or a history of such in first degree relatives.

- The participant is at increased risk for seizures for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or a history of significant head trauma with loss of consciousness for > 5 minutes.

- The participant has a history of head injury.

- The participant suffers from an unstable physical disease, such as high blood pressure (>150 mmHg systolic / diastolic > 110 mmHg) or acute, unstable cardiac disease The participant is at a high risk for severe violence or suicidal tendencies, assessed during the screening interview (see appendix 4).

- The participant has metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neuro-stimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps.

- The participant is having, or has had, any metal in the head (outside the mouth).

- The participant suffers from a significant neurological disorder or insult including, but not limited to:

- Any condition likely to be associated with increased intracranial pressure

- Space occupying brain lesion

- History of cerebrovascular accident

- Transient ischemic attack within the last two years

- Cerebral aneurysm

- Dementia

- Parkinson's disease

- Huntington's chorea

- Multiple sclerosis

- The participant has any cognitive or functional disability, according to criteria specified in the DSM-V, such as active psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-V; Axis I and Axis II) diagnosed within the last year.

- The participant has started or changed a psychotropic prescription within the last three months.

- The participant has current alcohol or other substance abuse or dependence, or has had one over the last 12 months prior to recruitment.

- The participant can't reliably communicate with the investigator, or is unlikely to cope with the requirements of the experiment.

- The participant is having a known or suspected pregnancy or lactation.

- The participant is a sexually-active woman of childbearing age, who does not use a medically accepted form of contraception.

- The motor threshold can't be found or quantified.

- The PI decides that the participant should be withdrawn from the study for the safety and welfare of the participant. For example, the participant experiences adverse event which is contraindicated with the continuation in the study.

- A history of intolerance to a TMS treatment.

- The participant asks for withdrawal

Study Design


Related Conditions & MeSH terms


Intervention

Device:
A multi-channel deep TMS device with an H-coil (Brainsway Ltd)
A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.

Locations

Country Name City State
Israel SorokaUMC Beer Sheva

Sponsors (2)

Lead Sponsor Collaborator
Soroka University Medical Center Ben-Gurion University of the Negev

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other General mood Positive Affect Negative Affect Schedule (PANAS) Change between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15)
Primary Change in weight Unit of measure: BMI in kg/m^2 (weight in kilograms, height in meters) Change in weight between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15)
Secondary Performance on a food Stroop test Unit of measure: reaction time (in milliseconds) Change in performance between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15)
Secondary Food addiction symptoms Yale Food Addiction Scale (YFAS) Change between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15)
Secondary Safety and tolerability of a PAS protocol using the multi-channel deep TMS system, measured via the number of adverse events (AE) Measured via the number of adverse events Throughout the study period, estimated as 2 years
Secondary Eating behavior (cognitive restraint, disinhibition, and hunger) Three Factor Eating Questionnaire (TFEQ) Change between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15)
Secondary Quality of life Health Status Scale Short-form 36 (SF-36) Change between baseline and the end of the treatment (day 15) and follow-up (a month after day 15)
Secondary Implementation of INP 1. Acute change in INP, assessed via changes in cortical excitability (measured via EEG and TCI) between pre- and post PAS administration. 2. Chronic change in INP assessed as change in cortical excitability between baseline versus the end of the treatment (day 15) and follow up (measured via EEG and TCI) Changes in cortical excitability between baseline versus following 15 days of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2